CV Sciences (OTCMKTS:CVSI)
- CEO:Joseph Dowling
CV Sciences (OTCMKTS:CVSI) Stock Price
Disclaimer: Past performance is not an indicator of future performance.
CV Sciences (OTCMKTS:CVSI) Company Overview
CV Sciences (OTC:CVSI) operates through two segments, Specialty Pharmaceuticals, and Consumer Products. The company focuses on developing and commercialising prescription drugs utilising synthetic cannabidiol (CBD) as the active pharmaceutical ingredient. Its initial drug candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction.
The company also engages in the development, manufacture, marketing, and sale of consumer products containing Hemp-based CBD under the PlusCBD Oil name in various market sectors, including nutraceutical, beauty care, specialty foods, and vape.
A well-run business with great management, and a solid track record, they are one of the best placed to take advantage of the massive Hemp market currently opening up across the US. The Farm Bill of 2018 has, without doubt, lifted the tides for all companies operating in the hemp-derived CBD space, and CV Sciences is primed to take advantage of this.
- Address:Suite B, 2688 South Rainbow Boulevard, Las Vegas, NV 89146, USA